School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Department of Pathology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
Neurochem Res. 2024 Jan;49(1):129-141. doi: 10.1007/s11064-023-04013-8. Epub 2023 Aug 29.
Periventricular leukomalacia (PVL), a predominant form of brain injury in preterm survivors, is characterized by hypomyelination and microgliosis and is also the major cause of long-term neurobehavioral abnormalities in premature infants. Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in mediating cell death and inflammatory signaling cascade. However, very little is known about the potential effect of RIPK1 in PVL and the underlying mechanism. Herein, we found that the expression level of RIPK1 was drastically increased in the brain of PVL neonatal mice models, and treatment of PVL neonatal mice with Necrostatin-1s (Nec-1s), an inhibitor of RIPK1, greatly ameliorated cerebral ischemic injury, exhibiting an increase of body weights, reduction of cerebral infarct size, neuronal loss, and occurrence of necrosis-like cells, and significantly improved the long-term abnormal neurobehaviors of PVL. In addition, Nec-1s significantly suppressed hypomyelination and promoted the differentiation of oligodendrocyte precursor cells (OPCs), as demonstrated by the increased expression levels of MBP and Olig2, the decreased expression level of GPR17, a significant increase in the number of CC-1-positive cells, and suppression of myelin ultrastructure impairment. Moreover, the mechanism of neuroprotective effects of Nec-1s against PVL is closely associated with its suppression of the RIPK1-mediated necrosis signaling molecules, RIPK1, PIPK3, and MLKL. More importantly, inhibition of RIPK1 could reduce microglial inflammatory injury by triggering the M1 to M2 microglial phenotype, appreciably decreasing the levels of M1 marker CD86 and increasing the levels of M2 markers Arg1 or CD206 in PVL mice. Taken together, inhibition of RIPK1 markedly ameliorates the brain injury and long-term neurobehavioral abnormalities of PVL mice through the reduction of neural cell necroptosis and reversing neuroinflammation.
脑室周围白质软化症(PVL)是早产儿幸存者中主要的脑损伤形式,其特征为少突胶质细胞发育不全和小胶质细胞增生,也是早产儿长期神经行为异常的主要原因。受体相互作用蛋白激酶 1(RIPK1)在介导细胞死亡和炎症信号级联反应中发挥关键作用。然而,关于 RIPK1 在 PVL 中的潜在作用及其潜在机制,人们知之甚少。在此,我们发现 RIPK1 的表达水平在 PVL 新生小鼠模型的大脑中显著增加,并且 RIPK1 抑制剂 Necrostatin-1s(Nec-1s)治疗 PVL 新生小鼠可显著改善脑缺血损伤,表现为体重增加、脑梗死面积缩小、神经元丢失和坏死样细胞发生减少,以及显著改善 PVL 的长期异常神经行为。此外,Nec-1s 还显著抑制少突胶质细胞发育不全,并促进少突胶质前体细胞(OPC)分化,表现为 MBP 和 Olig2 的表达水平增加,GPR17 的表达水平降低,CC-1 阳性细胞数量显著增加,以及髓鞘超微结构损伤得到抑制。此外,Nec-1s 对 PVL 的神经保护作用的机制与其抑制 RIPK1 介导的坏死信号分子(RIPK1、PIPK3 和 MLKL)密切相关。更重要的是,抑制 RIPK1 通过触发 M1 向 M2 小胶质细胞表型,可以减少小胶质细胞炎症损伤,使 PVL 小鼠中 M1 标志物 CD86 的水平显著降低,M2 标志物 Arg1 或 CD206 的水平显著升高。综上所述,通过减少神经细胞坏死性凋亡和逆转神经炎症,抑制 RIPK1 可显著改善 PVL 小鼠的脑损伤和长期神经行为异常。